MYOVANT SCIENCES LTD's ticker is MYOV and the CUSIP is G637AM102. A total of 108 filers reported holding MYOVANT SCIENCES LTD in Q3 2020. The put-call ratio across all filers is 1.27 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $854,982 | -99.9% | 31,713 | -2.3% | 0.00% | – |
| Q3 2022 | $582,676,000 | +44.5% | 32,443 | +0.0% | 0.00% | – |
| Q2 2022 | $403,254,000 | -6.7% | 32,442 | 0.0% | 0.00% | – |
| Q1 2022 | $432,127,000 | -14.5% | 32,442 | 0.0% | 0.00% | – |
| Q4 2021 | $505,122,000 | -30.6% | 32,442 | 0.0% | 0.00% | – |
| Q3 2021 | $727,999,000 | -1.4% | 32,442 | 0.0% | 0.00% | – |
| Q2 2021 | $738,705,000 | +21.1% | 32,442 | +9.5% | 0.00% | – |
| Q1 2021 | $609,785,000 | -44.5% | 29,630 | -25.5% | 0.00% | -100.0% |
| Q4 2020 | $1,099,083,000 | +121.3% | 39,793 | +12.6% | 0.00% | – |
| Q3 2020 | $496,611,000 | -50.8% | 35,346 | -27.8% | 0.00% | -100.0% |
| Q2 2020 | $1,009,328,000 | +417.3% | 48,949 | +89.4% | 0.00% | – |
| Q1 2020 | $195,115,000 | -57.7% | 25,843 | -13.0% | 0.00% | – |
| Q4 2019 | $460,789,000 | – | 29,690 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blackcrane Capital, LLC | 142,065 | $2,924,000 | 4.61% |
| Tri Locum Partners LP | 321,101 | $6,608,000 | 1.64% |
| PFM Health Sciences, LP | 2,054,928 | $42,290,000 | 1.29% |
| Bellevue Group AG | 5,194,039 | $106,893,000 | 1.13% |
| Pier Capital, LLC | 554,779 | $11,417,000 | 1.08% |
| Opaleye Management Inc. | 249,800 | $5,141,000 | 0.76% |
| Evolution Wealth Advisors, LLC | 140,227 | $2,886,000 | 0.64% |
| Hennion & Walsh Asset Management, Inc. | 399,330 | $8,218,000 | 0.49% |
| Cormorant Asset Management, LP | 1,000,000 | $20,580,000 | 0.46% |
| Integral Health Asset Management, LLC | 65,000 | $1,338,000 | 0.38% |